The AKT inhibitor, MK2206, currently in clinical trials for treating cancer [39], was shown to suppress expression levels of PD-L1 in tumor cells, enhance cluster of differentiation-positive (CD8+) T-cell infiltration, and inhibit tumor growth. Here, CD8A is linked to cancer.